2 enrolling by invitation, 1 withdrawn. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 3 | 2 | Enrolling by invitation 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Lisaftoclax: new trials by email Literature Review of Lisaftoclax trials Research Report on Lisaftoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 | |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Leukemia, Myeloid (2) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Induction Chemotherapy (2) · Opiate Substitution Treatment (2) · Azacitidine (1) · Cytarabine (1) · Granulocyte Colony-Stimulating Factor (1) · Lisaftoclax (1) · fludarabine (1) · pelcitoclax (1)
First Affiliated Hospital of Zhejiang University (2) · M.D. Anderson Cancer Center (1)
China (2)